Polmacoxib
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Acelex |
Other names | CG100649 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C18H16FNO4S |
Molar mass | 361.39g·mol−1 |
3D model (JSmol) | |
| |
|
Polmacoxib(trade nameAcelex) is anonsteroidal anti-inflammatory drug(NSAID) used to treatosteoarthritis.It was developed asCG100649and approved for use in South Korea in February 2015.[1]It inhibits the enzymescarbonic anhydraseandCOX-2. A study in healthy volunteers showed drug effects on urinaryprostaglandinmetabolites for both polmacoxib andcelecoxibthat suggest a similar cardiovascular risk profile.[2]Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies.[3]
References[edit]
- ^"CrystalGenomics Receives MFDS Approval for Acelex (Polmacoxib)"(Press release). PR Newswire.
- ^Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA (June 2012)."Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649".Clinical Pharmacology and Therapeutics.91(6): 986–93.doi:10.1038/clpt.2012.3.PMC3740579.PMID22278334.
- ^Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C (October 2013). "GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies".Clinical Pharmacology in Drug Development.2(4): 379–86.doi:10.1002/cpdd.47.PMID27121942.S2CID35992507.